Programmable vs Nonprogrammable Shunt Valves

Status: draft · Last updated 2026-10-23 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Shunt survival: randomized trial 52% vs 50% at 2 years, no difference . Cochrane RR 1.02 . HCRN: programmability and valve type don't predict failure .
  • Flow-regulated (Orbis-Sigma) valves: French series suggest longer survival (49% at 20 years, better than differential-pressure valves) and fewer slit ventricles. The randomized shunt design trial found no difference .
  • Observational meta-analyses suggest fewer revisions (RR 0.56) and fewer drainage complications with programmable valves, but they are prone to bias .
  • Main advantage: pressure can be adjusted without surgery. This helps most with over- or under-drainage and in complex patients like preterm posthemorrhagic hydrocephalus .
  • MRI: setting changes follow 27–57% of MRIs and vary by brand, from about 74% (Strata) to 0% (Strata MR, proGAV 2.0). Check before and after every MRI .
  • Everyday devices: risk exists only very close to the valve, mainly from magnetic toys and a tablet within about 2.5 cm. Headphones and phones used normally are safe .
  • Head growth in infants: programmable or adjustable valves can be used to counteract excessive head growth and to treat over- or under-drainage as the child grows . Overdrainage can instead cause craniocerebral disproportion .
  • Head size and survival: a larger head at shunting predicts malfunction (HC >27 cm in posthemorrhagic hydrocephalus) and early complications . Extreme macrocephaly carries high rates of wound breakdown, infection and death .

Landmark papers

  • Programmable valve trial (Pollack et al., Neurosurgery 1999): the only randomized trial of programmable vs conventional valves (377 patients). Among the 235 first shunt insertions, the original shunt survived 2 years without revision in 52% vs 50% .
  • Pediatric valve design trial (Drake et al., Neurosurgery 1998): a randomized trial in which the Orbis-Sigma valve, the Delta valve and standard differential-pressure valves had no difference in failure-free survival .
  • Cochrane review (Garegnani et al., Cochrane Database Syst Rev 2020): rated the programmable comparison low-certainty evidence, with treatment failure of 52% in both arms (RR 1.02) .

Does programmability change shunt survival?

The best evidence says no. In the only randomized trial (377 patients), among the 235 first shunt insertions the original shunt survived 2 years without revision in 52% with a programmable Codman Hakim valve vs 50% with a conventional valve. For revisions the figures were 43% in each arm. Valve survival, overall shunt survival and control of hydrocephalus were all comparable . A Cochrane review rated this comparison as low-certainty evidence and found treatment failure of 52% in both arms (RR 1.02) and similar adverse events (6.19% vs 6.01%) . Large prospective HCRN cohorts agree: neither valve programmability nor valve type was independently associated with shunt failure.

Pooled analyses that include observational studies are more favorable to programmable valves, but they carry selection bias:

Flow-regulated valves (Orbis-Sigma)

The Orbis-Sigma valve (OSV) is neither programmable nor a simple differential-pressure valve. It regulates flow rather than pressure, to limit overdrainage. French series from Necker-Enfants Malades suggest it may give longer shunt survival:

The randomized evidence does not confirm a survival advantage:

Taken together, the French data suggest a possible long-term survival benefit and less overdrainage with flow regulation. Those data are nonrandomized and historical, and the randomized trial showed no difference .

Advantages of programmable valves

Modulating head growth in infants

In infants with open sutures, the valve setting affects head growth as well as ventricular size. A programmable valve lets the surgeon adjust drainage as the head grows, rather than accept a single fixed setting:

Head size and shunt survival

Disadvantages and risks

Practical approach

Related topics

References

  1. Pollack IF, Albright AL, Adelson PD. A randomized, controlled study of a programmable shunt valve versus a conventional valve for patients with hydrocephalus. Neurosurgery 1999;45(6):1399–1408. doi:10.1097/00006123-199912000-00026. PMID 10598708. verified
  2. Garegnani L, Franco JV, Ciapponi A, et al. Ventriculo-peritoneal shunting devices for hydrocephalus. Cochrane Database Syst Rev 2020;6(6):CD012726. doi:10.1002/14651858.CD012726.pub2. PMID 32542676. verified
  3. Riva-Cambrin J, Kestle JR, Holubkov R, et al. Risk factors for shunt malfunction in pediatric hydrocephalus: a multicenter prospective cohort study. J Neurosurg Pediatr 2016;17(4):382–390. doi:10.3171/2015.6.PEDS14670. PMID 26636251. verified
  4. Ravindra VM, Kestle JRW, Jensen H, et al. Cerebrospinal fluid shunt failure in children is associated with medical complexity and shunt position, not shunt technology: a multicenter prospective study from the Hydrocephalus Clinical Research Network. J Pediatr 2026;300:115308. doi:10.1016/j.jpeds.2026.115308. PMID 42716243. verified
  5. Xu H, Wang ZX, Liu F, et al. Programmable shunt valves for the treatment of hydrocephalus: a systematic review. Eur J Paediatr Neurol 2013;17(5):454–461. doi:10.1016/j.ejpn.2013.04.001. PMID 23830575. verified
  6. Li M, Wang H, Ouyang Y, et al. Efficacy and safety of programmable shunt valves for hydrocephalus: a meta-analysis. Int J Surg 2017;44:139–146. doi:10.1016/j.ijsu.2017.06.078. PMID 28648796. verified
  7. Hatlen TJ, Shurtleff DB, Loeser JD, et al. Nonprogrammable and programmable cerebrospinal fluid shunt valves: a 5-year study. J Neurosurg Pediatr 2012;9(5):462–467. doi:10.3171/2012.1.PEDS10482. PMID 22546022. verified
  8. Hall BJ, Ali AMS, Hennigan D, et al. Hydrocephalus in prematurity: does valve choice make a difference? Childs Nerv Syst 2024;40(4):1091–1098. doi:10.1007/s00381-023-06204-8. PMID 37934253. verified
  9. Sordyl R, Wyroba N, Kardas N, et al. The application of programmable shunts in the management of hydrocephalus in pediatric patients. Childs Nerv Syst 2026;42(1). doi:10.1007/s00381-026-07210-2. PMID 41831117. verified
  10. Ucisik FE, Simonetta AB, Bonfante-Mejia EM. Magnetic resonance imaging-related programmable ventriculoperitoneal shunt valve setting changes occur often. Acta Neurochir (Wien) 2022;164(2):495–498. doi:10.1007/s00701-021-05060-2. PMID 34787715. verified
  11. O'Neill BE, Pfeuffer A, Soyland DJ, et al. Programmable shunt valve stability after MRI: a 2-year institutional experience across valve types and field strengths. Childs Nerv Syst 2026;42(1). doi:10.1007/s00381-026-07409-3. PMID 42562913. verified
  12. Zuzak TJ, Balmer B, Schmidig D, et al. Magnetic toys: forbidden for pediatric patients with certain programmable shunt valves? Childs Nerv Syst 2009;25(2):161–164. doi:10.1007/s00381-008-0770-x. PMID 19057906. verified
  13. Strahle J, Selzer BJ, Muraszko KM, et al. Programmable shunt valve affected by exposure to a tablet computer. J Neurosurg Pediatr 2012;10(2):118–120. doi:10.3171/2012.3.PEDS1211. PMID 22734456. verified
  14. Spader HS, Ratanaprasatporn L, Morrison JF, et al. Programmable shunts and headphones: are they safe together? J Neurosurg Pediatr 2015;16(4):402–405. doi:10.3171/2015.1.PEDS14400. PMID 26149436. verified
  15. Park M, Chaudhry M, Quadri N, et al. Impact of handheld and wearable electronics on programmable shunt valves. J Neurosurg Pediatr 2026;38(3):335–340. doi:10.3171/2026.2.PEDS25125. PMID 42398102. verified
  16. Auricchio AM, Bohnen A, Nichelatti M, et al. Management of slit ventricle syndrome: a single-center case series of 32 surgically treated patients. World Neurosurg 2022;158:e352–e361. doi:10.1016/j.wneu.2021.10.183. PMID 34749014. verified
  17. Bock HC, von Philipp G, Ludwig HC. An adjustable gravitational valve for initial VP-shunt treatment in hydrocephalic preterm neonates and infants below 1 year of age. Childs Nerv Syst 2021;37(11):3497–3507. doi:10.1007/s00381-021-05250-4. PMID 34152450. verified
  18. Korinth MC, Weinzierl MR, Gilsbach JM. Experience with a new concept to lower non-infectious complications in infants with programmable shunts. Eur J Pediatr Surg 2003;13(2):81–86. doi:10.1055/s-2003-39585. PMID 12776237. verified
  19. Carmel PW, Albright AL, Adelson PD, et al. Incidence and management of subdural hematoma/hygroma with variable- and fixed-pressure differential valves: a randomized, controlled study of programmable compared with conventional valves. Neurosurg Focus 1999;7(4):e7. doi:10.3171/foc.1999.7.4.2. PMID 16918220. verified
  20. Martínez-Lage JF, Ruiz-Espejo Vilar A, Pérez-Espejo MA, et al. Shunt-related craniocerebral disproportion: treatment with cranial vault expanding procedures. Neurosurg Rev 2006;29(3):229–235. doi:10.1007/s10143-006-0022-z. PMID 16534633. verified
  21. Iyer RR, Carey CM, Rottgers SA, et al. Early postnatal cranial vault reduction and fixation surgery for severe hydrocephalic macrocephaly. J Neurosurg Pediatr 2018;21(5):486–495. doi:10.3171/2017.11.PEDS17173. PMID 29498604. verified
  22. Bir SC, Konar S, Maiti TK, et al. Outcome of ventriculoperitoneal shunt and predictors of shunt revision in infants with posthemorrhagic hydrocephalus. Childs Nerv Syst 2016;32(8):1405–1414. doi:10.1007/s00381-016-3090-6. PMID 27278283. verified
  23. Santos MM, Rubagumya DK, Dominic I, et al. Infant hydrocephalus in sub-Saharan Africa: the reality on the Tanzanian side of the lake. J Neurosurg Pediatr 2017;20(5):423–431. doi:10.3171/2017.5.PEDS1755. PMID 28885096. verified
  24. Tuli S, O'Hayon B, Drake J, et al. Change in ventricular size and effect of ventricular catheter placement in pediatric patients with shunted hydrocephalus. Neurosurgery 1999;45(6):1329–1333. doi:10.1097/00006123-199912000-00012. PMID 10598700. verified
  25. Deora H, Thakur D, Shashidhar A, et al. Huge hydrocephalus: a rare case series with insights into management and outcomes of this neglected cohort. Childs Nerv Syst 2024;40(9):2905–2914. doi:10.1007/s00381-024-06495-5. PMID 38898287. verified
  26. Beuriat PA, Puget S, Cinalli G, et al. Hydrocephalus treatment in children: long-term outcome in 975 consecutive patients. J Neurosurg Pediatr 2017;20(1):10–18. doi:10.3171/2017.2.PEDS16491. PMID 28430083. verified
  27. Sainte-Rose C. Shunt obstruction: a preventable complication? Pediatr Neurosurg 1993;19(3):156–164. doi:10.1159/000120722. PMID 8499327. verified
  28. Hanlo PW, Cinalli G, Vandertop WP, et al. Treatment of hydrocephalus determined by the European Orbis Sigma Valve II survey: a multicenter prospective 5-year shunt survival study in children and adults in whom a flow-regulating shunt was used. J Neurosurg 2003;99(1):52–57. doi:10.3171/jns.2003.99.1.0052. PMID 12854744. verified
  29. Drake JM, Kestle JR, Milner R, et al. Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus. Neurosurgery 1998;43(2):294–303. doi:10.1097/00006123-199808000-00068. PMID 9696082. verified
  30. Henderson D, Budu A, Zaki H, et al. A comparison between flow-regulated and adjustable valves used in hydrocephalus during infancy. Childs Nerv Syst 2020;36(9):2013–2019. doi:10.1007/s00381-020-04552-3. PMID 32152667. verified

Verification (2026-10-23): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed, and every figure cited was checked against the PubMed abstract. Full texts were not reviewed. The "Practical approach" section and the practical implication of head size are this text's synthesis of the cited evidence, not a published guideline.